CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma
Journal of Nuclear Medicine · 2025-09 · 66 (9) · 1400-1405
DOI: 10.2967/jnumed.125.270167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 31.07.2025. Verfasst von Hima Makala und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and. Hauptthemen laut MEDLINE: CD24 Antigen, Carcinoma, Hepatocellular, Liver Neoplasms, Radiopharmaceuticals. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. After the use of liver-directed therapies, it is challenging to differentiate between nonviable tumor and viable residual or recurrent disease using conventional imaging techniques. Targeted radiopharmaceutical imaging agents with specificity for HCC-selective molecules may address this unmet need. CD24, a glycosylated plasma membrane protein, is overexpressed in HCC. Here, we describe a CD24-targeted antibody-based PET (immuno-PET) tracer for the noninvasive detection of CD24-positive (CD24+) tumors.
Methods
CD24 expression was assessed at the messenger RNA, total protein, and cell membrane levels across 4 HCC cell lines (Huh7, Hep3B, SNU182, SNU449), 1 hepatoblastoma line (HepG2), and a CD24+ colorectal cancer-positive control line (HT29) using quantitative reverse transcription polymerase chain reaction, Western blot testing, and flow cytometry. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9-mediated CD24 gene knockout was performed in SNU449, Hep3B, and HT29 cells to yield otherwise isogenic cell lines as CD24-negative (CD24-) controls. The binding affinity of a humanized monoclonal anti-CD24 antibody (α-hCD24) for recombinant CD24 protein was confirmed by biolayer interferometry and enzyme-linked immunosorbent assay. We then synthesized the immuno-PET tracer ([89Zr]Zr-desferrioxamine [DFO]-α-hCD24) and assessed target engagement in vivo using PET/CT imaging and ex vivo by evaluating the biodistribution of xenograft models using paired CD24+ and CD24- HCC and HT29 isogenic cell lines in athymic nude mice.
Results
Huh7, Hep3B, SNU449, and HT29 cell lines demonstrated high total and plasma membrane expression of CD24. The α-hCD24 antibody exhibited good binding affinity to recombinant human CD24 (dissociation constant, 2.4 nM) and was unaffected by DFO conjugation of α-hCD24 (dissociation constant, 2.7 nM). [89Zr]Zr-DFO-α-hCD24 was efficiently produced at high radiochemical yield (75% ± 5%) and radiopurity (99% ± 1%). PET/CT imaging and biodistribution studies confirmed specific uptake of [89Zr]Zr-DFO-α-hCD24 in Hep3B CD24+ tumors (8.7 ± 1.2 %IA/g) and much lower accumulation in Hep3B CD24- tumors (2.3 ± 0.6 %IA/g) at 144 h after injection.
Conclusion
Our findings establish CD24 as a promising radiotheranostic target for HCC. Future work will optimize [89Zr]Zr-DFO-α-hCD24 to improve tumor-to-liver signal and facilitate CD24-targeted radiopharmaceutical therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and.
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and freddy.escorcia@nih.gov.
- Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Förderung
- Intramural NIH HHS
Zitieren
APA
Makala, H., Sheehan-Klenk, J., Lee, W., Chung, J. Y., Baidoo, K. E., Nambiar, D., Choyke, P. L., & Escorcia, F. E. (2025). CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma. Journal of Nuclear Medicine, 66(9), 1400-1405. https://doi.org/10.2967/jnumed.125.270167
Vancouver
Makala H, Sheehan-Klenk J, Lee W, Chung JY, Baidoo KE, Nambiar D, et al. CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma. Journal of Nuclear Medicine. 2025;66(9):1400-1405. doi:10.2967/jnumed.125.270167
BibTeX
@article{Makala2025,
author = {Makala, Hima and Sheehan-Klenk, Julia and Lee, Woonghee and Chung, Joon-Yong and Baidoo, Kwamena E and Nambiar, Divya and Choyke, Peter L and Escorcia, Freddy E},
title = {CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma},
journal = {Journal of Nuclear Medicine},
year = {2025},
volume = {66},
number = {9},
pages = {1400--1405},
doi = {10.2967/jnumed.125.270167}
}
EUVIMED